NCT02545933View on ClinicalTrials.gov

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

PHASE4CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

January 31, 2020

Conditions
Myocardial Infarction
Interventions
DRUG

Prasugrel

Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)

DRUG

Vorapaxar

Vorapaxar will be administered at the dose of 2.5mg once daily

DRUG

Aspirin

Aspirin will be administered at the dose of 81mg once daily

DRUG

Ticagrelor

Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Florida

OTHER

NCT02545933 - Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor | Biotech Hunter | Biotech Hunter